Alzheimer’s researchers have proposed a radical change in the way the disease is defined, focusing on biological changes in the body rather than clinical symptoms such as memory loss and cognitive decline.
The new research framework, released on Tuesday by the Alzheimer’s Association and the National Institute on Aging, is meant to provide scientists with a common language for describing the disease in research studies based on measurable changes in the brain that set Alzheimer’s apart from other causes of dementia.
“Much of the general public views the terms dementia and Alzheimer’s disease as interchangeable, but they are not,” said Dr Clifford Jack of the Mayo Clinic in Rochester, Minnesota, who helped craft the guidelines.
The proposed changes follow guidance announced earlier this year by the US Food and Drug Administration and the European Medicines Agency to encourage the testing of new Alzheimer’s medicines based on biomarkers, rather than on clinical symptoms.
The moves would allow companies to test drugs in people before symptoms appear, offering a better chance of intervening before the disease has destroyed too many brain cells.
Under the proposed research framework, Alzheimer’s would be characterised by three factors: evidence of two abnormal proteins associated with Alzheimer’s – beta amyloid and tau – and evidence of neurodegeneration or nerve cell death, all of which can be seen through brain imaging or tests of cerebral spinal fluid.
It also incorporates measures of severity using biomarkers and a grading system for cognitive impairment.
The hope is that the new definition will help researchers pick better subjects on which to test new Alzheimer’s treatments, which may help improve drug companies’ search for treatments.Do you have an idea for a story?
Email [email protected]